Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

yttrium Y 90 ibritumomab tiuxetan

A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90). Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:90Y ibritumomab tiuxetan
IDEC-Y2B8 monoclonal antibody
Y90 Zevalin
Code name:IDEC Y2B8
NSC code:710085
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search